额叶皮层金字塔神经元表达特征区分了前性阶段与阿尔茨海默氏病谱中的渐进性退化
Amanda Labuza1,2, Melissa J Alldred1,2, Harshitha Pidikiti1
1Center for Dementia Research, Nathan Kline Institute, Orangeburg, New York, USA.
概括
研究人员在阿尔茨海默病 (AD) 进展过程中确定了大脑细胞中的关键分子差异. 这些发现揭示了不同的基因表达模式,可以指导早期诊断和AD的治疗策略.
科学领域:
- 神经科学是一个神经科学.
- 基因组学就是基因组学.
- 分子生物学分子生物学
背景情况:
- 阿尔茨海默病 (AD) 的精确分子基础仍然难以捉摸,需要确定控制其发病和进展的机制.
- 了解细胞脆弱性和确定治疗点对于开发有效的干预措施至关重要,特别是在AD的早期阶段.
研究的目的:
- 确定差异表达基因 (DEGs) 和区分正常认知,轻度认知障碍 (MCI) 和阿尔茨海默病 (AD) 的生物途径.
- 提供一个分子路线图,以了解皮层细胞脆弱性,并精确地确定AD的早期治疗点.
主要方法:
- 激光捕获微解剖被用来隔离从死后人类前额叶皮层 (Brodmann区域9) 的第三层金字塔神经元.
- 单个人群RNA测序是在没有认知障碍 (NCI),MCI和AD的个体的组织样本上进行的.
- 对差异表达基因 (DEGs) 的比较分析在NCI,MCI和AD组中进行.
主要成果:
- 与NCI相比,DEG的数量逐渐从MCI (prodromal AD) 增加到AD (frank AD).与NCI相比,DEG的数量逐渐增加.
- 基因表达模式显示出prodromal和进展阶段之间的不同方向变化,但进展和坦率AD之间的变化趋同.
- 生物能量路径在AD频谱中呈现出越来越多的失调,而免疫反应路径在坦率的AD中比在前期阶段更为明显.
结论:
- 特定的DEG,生物通路和相互作用组集有效地划分了AD频谱的不同阶段.
- 确定了候选基因和途径,可以作为早期AD发病和进展的生物标志物.
- 这些发现为研究皮质细胞脆弱性和为早期的AD开发有针对性的干预措施提供了路线图.
相关概念视频
Alzheimer's Disease: Overview
669
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
669
Neural Regulation
40.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
40.1K
Parkinson's Disease: Overview
710
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
710


